正清风痛宁片治疗IgA肾病中等量蛋白尿的疗效

Abstract
Figure/Table
References
Related Citation (13)

Download: PDF (603 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the safety and efficacy of Zhengqiang Fengtongning Tablets in the treatment of IgA nephropathy with moderate amount of proteinuria. Methods 156 patients with IgA nephropathy with moderate amount of proteinuria (urine protein quantitation: 1-3 g/24 h) were randomly divided into two groups. The study group was given Zhengqiang Fengtongning Tablets with valsartan and control group was given valsartan alone for treatment. The dosage of Zhengqiang Fengtongning was 2 tablets, 3 times a day, and valsartan was 80 mg/day. Results After treatment for 6 months, the total effective rate in the study group was significantly higher than that in the control group( 87.2% vs 56.4%, P＜0.01). 24 h urinary protein in the study group was significantly lower than that in the control group(1.59±0.66, P＜0.05). There were no differences in serum albumine, serum creatinine (Scr) , total protein (TP), total cholesterol (TC), and incidence of adverse reactions between the two groups. Conclusions Zhengqiang Fengtongning Tablets combined with valsartan for the treatment of IgA nephropathy with moderate amount of proteinuria is safe and reliable, which is worthy of clinical application.

Key words： IgA nephropathy Zhengqiang Fengtongning Tablets valsartan

Received: 10 April 2014

ZTFLH:

R943.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Wen
	GAO De
	ZHU Jing
	HE Xiao

Cite this article:

WANG Wen,GAO De,ZHU Jing等. Efficacy of Zhengqiang Fengtongning Tablets in the treatment of IgA nephropathy with moderate amount of proteinuria[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2014, 25(10): 1021-1023.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2014/V25/I10/1021

[4]	毛心辉,盛梅笑.IgA肾病中医治疗进展[J].中国中医急症,2011,20(7):1128-1130.
[5]	杨艳光,汪国翔,黄国东.IgA肾病中医诊治研究进展分析[J].内科,2012,7(5):546-548.
[1]	张宏.KDIGO指南解读:IgA肾病治疗[J].中国实用内科杂志,2012,32(12):925-927.
[6]	余仁欢.正清风痛宁片干预IgA肾病蛋白尿的临床疗效评价[J].中国中西医结合肾病杂志,2010,23(8):721-722.
[2]	谢静远,陈楠.IgA肾病的临床进展[J].中国实用内科杂志,2011,31(2):90-93.
[7]	Lee H S, Lee M S, Lee S M, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system[J]. Nephrol Dial Transplant, 2005, 20(2):342-348.
[3]	Samuels J A, Strippoli G F, Graig J C ,et al. Immunosuppressive treatments for immunoglobulin a nephropathy: a meta-analysis of randomized controlled trials[J]. Nephrology ,2004,9(4):177-185.
[8]	Yang Y,Ohta K,Shimizu M,et al.Treatment with low-dose angiotensin-converting enzyme inhibitor(ACEI) plus angiotensin Ⅱ receptor blocker(ARB)in pediatrics patients with IgA nephrology[J].Clin Nephrol,2005,64(1):35-40.
[4]	毛心辉,盛梅笑.IgA肾病中医治疗进展[J].中国中医急症,2011,20(7):1128-1130.
[9]	程悦,张静波,袁发焕.青藤碱在治疗自身免疫性疾病中的作用机制研究[J].中国中西医结合肾病杂志,2008,9(11):1025-1027.
[5]	杨艳光,汪国翔,黄国东.IgA肾病中医诊治研究进展分析[J].内科,2012,7(5):546-548.
[10]	Cheng Y,Zhang J,Hou W,et al.Immunoregulatoy effects of sinomenine on the T-bet/GATA-3 ratio and Th1/ Th2 cytokine balance in the treatment of mesangial proliferative nephritis[J].Int J Immunopharmacol,2009,9(7):894-899.
[11]	王毅,陈正,熊烈,等.青藤碱对肾移植大鼠急性排斥反应及T细胞增殖的影响[J].中华实用外科杂志,2004,21(5):573-574.
[6]	余仁欢.正清风痛宁片干预IgA肾病蛋白尿的临床疗效评价[J].中国中西医结合肾病杂志,2010,23(8):721-722.
[12]	叶木荣,刘良,曾元儿,等.青藤碱在大鼠体内分布与脏器毒理的关系研究[J].中国药理学通报,2001,17(1):65-69.
[7]	Lee H S, Lee M S, Lee S M, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system[J]. Nephrol Dial Transplant, 2005, 20(2):342-348.
[13]	邹敏书,余健,聂国明,等.IgA肾病及过敏性紫癜性肾炎患儿血清半乳糖缺乏IgA1测定的临床意义[J]. 华南国防医学杂志,2012,26(6):542-544.
[14]	吴丽丹,刘华锋,卓华钦,等.局灶-节段性肾病患者蛋白尿促肾间质纤维化的探讨[J]. 华南国防医学杂志,2013,27(7):455-458.
[15]	赵林双,向光大,乐岭,等.糖尿病肾病患者血清抗AT1和α1受体抗体与肾小球滤过率的关系[J]. 华南国防医学杂志,2012,26(5):448-451.
[8]	Yang Y,Ohta K,Shimizu M,et al.Treatment with low-dose angiotensin-converting enzyme inhibitor(ACEI) plus angiotensin Ⅱ receptor blocker(ARB)in pediatrics patients with IgA nephrology[J].Clin Nephrol,2005,64(1):35-40.
[9]	程悦,张静波,袁发焕.青藤碱在治疗自身免疫性疾病中的作用机制研究[J].中国中西医结合肾病杂志,2008,9(11):1025-1027.
[10]	Cheng Y,Zhang J,Hou W,et al.Immunoregulatoy effects of sinomenine on the T-bet/GATA-3 ratio and Th1/ Th2 cytokine balance in the treatment of mesangial proliferative nephritis[J].Int J Immunopharmacol,2009,9(7):894-899.
[11]	王毅,陈正,熊烈,等.青藤碱对肾移植大鼠急性排斥反应及T细胞增殖的影响[J].中华实用外科杂志,2004,21(5):573-574.
[12]	叶木荣,刘良,曾元儿,等.青藤碱在大鼠体内分布与脏器毒理的关系研究[J].中国药理学通报,2001,17(1):65-69.
[13]	邹敏书,余健,聂国明,等.IgA肾病及过敏性紫癜性肾炎患儿血清半乳糖缺乏IgA1测定的临床意义[J]. 华南国防医学杂志,2012,26(6):542-544.
[14]	吴丽丹,刘华锋,卓华钦,等.局灶-节段性肾病患者蛋白尿促肾间质纤维化的探讨[J]. 华南国防医学杂志,2013,27(7):455-458.
[15]	赵林双,向光大,乐岭,等.糖尿病肾病患者血清抗AT1和α1受体抗体与肾小球滤过率的关系[J]. 华南国防医学杂志,2012,26(5):448-451.